Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of the mTOR inhibitor everolimus as maintenance therapy in elderly patients with mantle cell lymphoma
2007-005116-12Phase 2Terminated
- Sponsor
- Technical University of Munich
- Start
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in mantle cell lymphoma (MCL), sponsored by Technical University of Munich. Primary endpoint: Time to progression. Started Nov 2007; status: terminated.
02
Drugs
everolimus
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2007-005116-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005116-12.